<DOC>
	<DOCNO>NCT01310114</DOCNO>
	<brief_summary>The primary objective study assess safety tolerability Human Placenta-Derived Cells ( PDA001 ) 3 different dose level versus placebo ( vehicle control ) administer intravenously subject follow ischemic stroke . The secondary objective study assess effect PDA001 improvement clinical function follow ischemic stroke .</brief_summary>
	<brief_title>Study Human Placenta-derived Cells ( PDA001 ) Evaluate Safety Effectiveness Patients With Ischemic Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Infarction , Middle Cerebral Artery</mesh_term>
	<mesh_term>Infarction , Posterior Cerebral Artery</mesh_term>
	<criteria>Inclusion Criteria 1 . Males females 18 year age 80 year age time sign informed consent document . 2 . Subject subject 's legal representative must understand voluntarily sign informed consent document prior studyrelated assessments/procedures conduct . 3 . Able adhere study visit schedule protocol requirement . 4 . A female childbearing potential ( FCBP ) must negative serum urine pregnancy test within 48 ± 24 hour prior treatment study therapy . In addition , sexually active FCBP must agree use two follow adequate form contraception method simultaneously : oral , injectable implantable hormonal contraception ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomize partner duration study followup period . Males ( include vasectomy ) must agree use barrier contraception ( latex condom ) engage reproductive sexual activity FCBP duration study followup period . 5 . Diagnosis stroke involve middle cerebral artery ( MCA ) territory ( cortical subcortical ) posterior cerebral artery ( PCA ) ( PCA limit 3 subject per cohort ) ischemic stroke confirm magnetic resonance imaging ( MRI ) / computerize tomography ( CT ) . An ischemic stroke death area brain tissue ( cerebral infarction ) result inadequate supply blood oxygen brain . 6 . National Institute Health Stroke Scale ( NIHSS ) score ≥ 6 &lt; 20 time screen infusion . Subject show rapid improvement ( ≥ 8 point decrease ) deterioration ( ≥ 4 point increase ) score time initial evaluation preinfusion . To extent possible , time initial screen evaluation reevaluation least 24 hour . 7 . Subject must normal neurologic status prior ischemic episode define absence focal global central neurological psychiatric deficit sufficient magnitude could reasonably expect subject could recover normal range base instrument use ass subject 's response treatment . The prestroke modify Rankin score 0 2 inclusive . 8 . Treatment tissue plasminogen activator ( tPA ) Food Drug Administration ( FDA ) approve device use restore circulation allow treatment must complete least 24 hour prior administration PDA001 . Exclusion Criteria 1 . Any significant medical condition , laboratory abnormality , psychiatric illness would prevent subject subject 's legal representative signing informed consent form . 2 . Pregnant lactating female . 3 . Any condition , include medical neuropsychiatric condition , include presence laboratory abnormality , judgment investigator place subject unacceptable risk he/she participate study confounds ability interpret data study include ( limited ) : Aspartate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) &gt; 2.5 x upper limit normal screening . Serum creatinine concentration &gt; 1.5 time upper limit normal screening . Bilirubin alkaline phosphatase level &gt; 2.5 x upper limit normal screening . Glucose &lt; 50 mg/dL &gt; 250 mg/dL despite adequate antihyperglycemic treatment . Platelet count &lt; 100 x 109 per liter . History bacteremia serious bacterial fungal infection require treatment IV antibiotic within 84 day ( 12 week ) prior treatment study therapy treat urinary tract infection . Known infection human immunodeficiency virus ( HIV ) . Seropositive hepatitis C hepatitis B . Known history seizure . 4 . Severe heart failure evidence acute myocardial infarction define least two follow three feature : ( 1 ) Chest pain suggestive cardiac ischemia ; ( 2 ) Electrocardiogram ( ECG ) finding ST elevation great 0.2 mV 2 contiguous lead , new onset leave bundle branch block , ST segment depression , Twave inversion ; ( 3 ) Elevated troponin I . History prior myocardial infarction within previous 6 month . 5 . Evidence prior cerebral hemorrhage ischemic stroke within last 3 month recent intracerebral hematoma head CT MRI . This exclusion include clinically insignificant petechial hemorrhage . 6 . Subjects lacunar infarct MRI CT. A lacunar infarct define small ( 0.2 15 mm diameter ) noncortical infarct cause occlusion single penetrate branch large cerebral artery . 7 . Persistent hypertension systolic blood pressure ( BP ) great 185 mmHg diastolic BP great 110 mmHg ( mean 3 consecutive arm cuff reading 2030 minute ) , control antihypertensive therapy require nitroprusside control . Efforts make bring systolic blood pressure ( BP ) ≤ 160 diastolic BP ≤ 100 mmHg time IP administration . 8 . Clinically significant pulmonary dysfunction , include severe chronic obstructive pulmonary disease ( COPD ) history lung resection . 9 . High clinical suspicion septic embolus . 10 . History pulmonary emboli deep vein thrombus 11 . History major trauma time stroke 12 . History malignancy within 5 year except basal cell squamous cell carcinoma skin remote history cancer consider cure positive Pap smear subsequent negative follow . 13 . Known allergy bovine porcine product . 14 . Known allergy gadolinium iodine base contrast agent MRI CT scan prevent ability conduct either one procedure . 15 . Subject receive investigational agent —an agent device approve FDA market use indication—within 90 day ( 5 halflives , whichever long ) prior treatment study therapy plan participation another therapeutic trial prior completion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Human Placenta-Derived Cells</keyword>
	<keyword>Stem cell</keyword>
	<keyword>Stroke</keyword>
	<keyword>PDA001</keyword>
	<keyword>Celgene</keyword>
	<keyword>cenplacel-L</keyword>
</DOC>